Francesco Massari

The never ending story. An unmet need for #rcc Which #biomarkers for #immunotherapy in advanced renal cell carcinoma? ⚠️ Out now our work just published on @NatRevUrol Thanks to my terrific GU Team 🙏 @vmollica7 @OncoAlert @onconetwork @Uromigos @urotoday

@VaneJuice Sempre tutta colpa di quello scudetto del Lecce primavera

Direi che stasera la Nazionale è a un punto di non ritorno, ma quel punto l'ha già superato due volte e non è cambiato nulla

⚡️ New SITC clinical practice guideline (v3.0) on immunotherapy in RCC: practical recommendations across adjuvant + metastatic settings, special populations, response monitoring, and QoL. Key reminders: PD-L1/TMB/MSI don’t guide selection; sarcomatoid features favor IO—nivo/ipi remains a preferred option. #KidneyCancer #RCC @crisbergerot @OncoAlert jitc.bmj.com/content/14/3/e…

Update dated data from CALYPSO (phase 2 Sav+durva in papillary RCC). Here the focus is on ctDNA @drfrankiejs shows most patients are positive (informed approach) and dynamic changes occur with thrapy which are prognostic. ctDNA maybe more useful in papillary than Clear cell RCC @JCO_ASCO @BartsECMC @crisuarez08 @OncoAlert

@JuveFaCose E aveva capito anche che avrebbe calciato di merda

Muric aveva capito un quarto d’ora prima che tirava là x.com/forvetdayi/sta…

Just in: The phase 3 Talapro-3 trial met its primary endpoint!!! fiercepharma.com/pharma/pfizer-… @OncoAlert @AUC3_Official

@aron_project at #EAU26 with the fantastic oral presentation by @vmollica7 @EUplatinum @Uromigos @urotoday @MatteoSantoniMD

Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario? frontiersin.org/journals/immun… Over the past decade, immunotherapy🧪 and novel agents have improved outcomes in metastatic urothelial carcinoma (mUC), yet liver metastases remain a poor prognostic factor. In a retrospective study across 79 institutions, outcomes were evaluated in patients receiving pembrolizumab post-platinum (n=1,341) or avelumab maintenance (n=291). Liver metastases significantly reduced overall survival in both cohorts, while higher BMI and better ECOG status predicted improved outcomes. Immunotherapy still outperformed historical chemotherapy survival overall. @drenriquegrande @Sebastiano_Buti @shilpaonc @fmassari79 @SoaresAndrey @MatteoSantoniMD @ravikanesvaran @Alerizzobranca #EAU26

@at3rzz Questa sciarpa è immensamente stupenda .. come puó acquistare?

Domenica magnifica: -3pt pe lu Lecce -nuova sciarpa Curva Nord Avanti Lecce💛❤️

⚡️ Neoadjuvant systemic therapy is reshaping GU oncology: in MIBC, cisplatin-based NAC remains standard (with expanding options like EV+pembro and IO combos, plus emerging ctDNA-guided adjuvant strategies). In RCC, neoadjuvant therapy is still investigational—early IO±TKI trials show feasibility and occasional pCR, but validated pathologic response criteria and surrogacy are still lacking. #BladderCancer #KidneyCancer @JCO_ASCO ascopubs.org/doi/full/10.12…

Papillary RCC is not one disease. What matters most? Biology. • FH-deficient • MET-driven • Classic • MiT translocation Most patients → ICI + TKI backbone. Treat the mutation. Not just the morphology. #RCC #KidneyCancer #PrecisionOncology #MVOnco

@DrIacovelli @DrChoueiri @ReneeSaliby @motzermd @jpsade2 @sscnapoli @Argentina @OncoAlert @DanaFarber @DanaFarberNews @ASCO @Mustafajsalehmd @tompowles1 1-2 at the end 😂

@DrChoueiri @ReneeSaliby @motzermd @jpsade2 @sscnapoli @Argentina @OncoAlert @DanaFarber @DanaFarberNews @ASCO @Mustafajsalehmd @tompowles1 Napoli scored 1:1 today! 😅

Starting this morning #GU26 with 2 practice changing trials in RCC with @motzermd and thank you @jpsade2 for the @sscnapoli and @Argentina ⚽️ @OncoAlert

Cabozantinib is hard to beat making this a standard !!

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.

A very important news for our patients #bladdercancer @AssPalinuro

While #COSMIC313 showed that triplet combo in 1L mRCC may not be the full answer (yet), this practice-informing study sheds light on useful biomarkers of response— @Annals_Oncology @myESMO @motzermd @tompowles1 @AlbigesL

Practice-changing study? The final EMBARK analysis shows an overall survival benefit with enzalutamide + ADT in high-risk biochemical recurrence prostate cancer. 👉 So which patients should be selected? • PSA-DT ≤9 months • PSA ≥1 ng/mL (post-RP) • or nadir +2 ng/mL (post-RT) • M0, castration-sensitive disease 📊 8-yr OS: 78.9% vs 69.5% (HR 0.60) Not for every biochemical recurrence — but practice-changing in this high-risk population. #OncoDaily #OncoAlert #OncoLive @OncBrothers @urotoday

Proud of my friend Rob

A full day of debate, evidence and shared perspectives comes to an end at @IstTumori. Thank you to all speakers, participants and partners for contributing to "Controversies in Genitourinary Tumors". See you next year! #ClinicalResearch #GUoncology #ControversiesinGU2026

Tomorrow 22/01/2026 in Milan: Controversies in Genitourinary Tumors  at @IstTumori. A deep dive into prostate, kidney, urothelial & rare GU cancers: new therapies, biomarkers, AI and real debates. Don’t miss it! #ClinicalResearch #Oncology #Genitourinary #ScientificEvent